Can deep sleep or nerve stimulation flush toxic proteins from the brain?
NCT ID NCT06421532
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants will be randomly assigned to one of the treatments for three months. The main goal is to measure changes in amyloid levels in spinal fluid, with brain scans used to track disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lower-sodium oxybate (XYWAV) and non-invasive vagus nerve stimulation (gammaCore Sapphire)
What this could lead to
If successful, this could point toward a new way to clear harmful protein buildup in the brain and slow disease progression in cerebral amyloid angiopathy.
What could go wrong
This is a small, early-phase trial (60 people) testing a biomarker, not a clinical outcome. The interventions may not improve symptoms or prevent bleeding, and side effects from the drug or device are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL AMYLOID ANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Leiden University Medical Center (LUMC)
Leiden, 2333ZA, Netherlands